Healthy Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers
Verified date | August 2020 |
Source | Galera Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will be a Phase 1, randomized, double-blind, placebo-controlled, single dose escalation study designed to evaluate the safety and PK of intravenously administered superoxide dismutase mimetic GC4711 in healthy volunteers.
Status | Completed |
Enrollment | 70 |
Est. completion date | March 4, 2020 |
Est. primary completion date | March 4, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy men and women between 18 and 50 years 2. Subjects who provide written informed consent 3. Body Mass Index (BMI) of 18 to 32 kg/m2 and weighing at least 50 kg 4. Subjects in general good health 5. Blood pressure and pulse within normal limits 6. Male subjects must practice effective contraception 7. Female subjects must: - Have a negative serum pregnancy test during - Be non-lactating; - Be at least 2 years postmenopausal, surgically sterile, or practicing effective contraception. Exclusion Criteria: 1. History of clinically significant illness or medical history which would preclude them from the study. 2. Known contraindication, hypersensitivity and/or allergy to study drugs 3. Use of any prescription or over-the-counter medication within one week prior to study drug administration 4. Anticipated need for any medication during the study 5. Use of nitrates or erectile dysfunction drugs such as phosphodiesterase type 5 (PDE 5) inhibitors 6. Use of other drugs that may, in the judgment of the Investigator, create a risk for a precipitous decrease in blood pressure 7. Presence of orthostatic hypotension at screening 8. Use of any vitamin or mineral supplement 24 hours before dosing or throughout study 9. Positive human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) 10. Known history of substance abuse, drug addiction, or alcoholism within 3 years 11. Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours before the administration of study drug and throughout the the study; 12. Positive drug and alcohol toxicology screens during Screening 13. History of smoking or any use of a tobacco product within 6 months 14. Donation of blood or blood products within 30 days before Baseline and throughout the study; 15. Mentally unstable or incapable of being compliant with the protocol 16. Receipt of an investigational test substance within 3 months before the administration of study drugs, or anticipated receiving any study drugs 17. Subject has previously participated in this study, or in a prior Galera study |
Country | Name | City | State |
---|---|---|---|
Australia | Nucleus Network | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Galera Therapeutics, Inc. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities | Number of Participants With Treatment-Emergent Adverse Events and/or Laboratory Abnormalities | From randomization through study completion (estimated up to 3 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |